icone plus
Contact Abonnez-vous aux actualités
Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
no clinical added value
EYLEA does not provide any improvement in actual benefit (level V, non-existent) compared with LUCENTIS for adults in the treatment of visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO).
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
n42ngxMYfUx37NMC
Listen
